Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

Supplemental Figure S1. A, pretreatment bone marrow samples were treated diluent (-) with 10 μM melphalan (+) for 6 h and analyzed by immmunoblotting for FANCD2, ubiquitinated FANCD2 (Ub-FANCD2) and, as a loading control, heat shock protein 90 (HSP90). Supplemental Figure S2. A, Aliquots of whole cell lysates containing 5 x 106 pretreatment marrow mononuclear cells from the indicated patients were subjected to SDS-PAGE and blotting for the indicated antigens (lanes 5-12). Supplemental Figure S3. A, PAR suppression in PBMCs at various veliparib dose levels as a function of times during therapy. B, PAR suppression in PBMCs at 2 hours post dosing on day 1 and its relationship to clinical response. C, PAR suppression as assessed in bone marrow aspirates. Supplemental Table S1. MPN-Associated Leukemia Characteristics Supplemental Table S2 Accumulation of γH2AX in Viable Peripheral Blood CD34+ Cells Following Veliparib Administration at 80 mg Twice Daily Relative to Pretreatment (Day 0) Levels of DNA Damage